<DOC>
	<DOCNO>NCT01762982</DOCNO>
	<brief_summary>The aim study evaluate irritation potential benzalkonium chloride disinfectant spray place contact normal human skin .</brief_summary>
	<brief_title>Patch Test Benzalkonium Chloride Disinfectant Spray</brief_title>
	<detailed_description>Benzalkonium chloride recognize safe effective short term use first aid antiseptic drug product . In study , benzalkonium chloride disinfectant spray compare positive control , two negative control irritancy potential normal skin accord Chinese Patch Test Guideline ( China Health Authority 2002 ) . The skin irritation assessment characterize test product individually term symptomatology use 5-point categorical scale range 0 ( visible reaction ) 4 ( Erythema , edemaË› extreme blistering ) .</detailed_description>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Benzalkonium Compounds</mesh_term>
	<mesh_term>Disinfectants</mesh_term>
	<criteria>1 . Consent : Demonstrates understand study willingness participate evidence voluntary write informed consent receive sign date copy inform consent form . 2 . Compliance : Understands willing , able likely comply study procedure restriction , agree participate study entire length study . 3 . General Health : Good general health ( opinion investigator ) clinically significant relevant abnormality medical history vital sign screen . 4 . Contraception : Females childbearing potential , opinion investigator , practise reliable method contraception . 1 . Pregnancy : Woman pregnant positive urine pregnancy test ( female childbearing potential ) baseline . 2 . Breastfeeding : Woman breastfeed . 3 . Allergy/Intolerance : Known suspected intolerance hypersensitivity study material selfreported `` sensitive skin '' history dermal hypersensitivity . 4 . Clinical Study/Experimental Medication : Participation another clinical study receipt investigational drug within 30 day screen visit , include take part predictive irritation study sensitisation test . 5 . Substance abuse : Recent history ( within last 1 year ) alcohol substance abuse . 6 . Personnel : An employee sponsor study site member immediate family . 7 . Participant currently take follow medication : Any topical systemic treatment may mask interfere test result , specifically topical and/or systemic corticosteroid , non steroidal antiinflammatory drug ( e.g . ibuprofen , aspirin ) , antihistamine immunosuppressive past 30 day . And take medication opinion clinical investigator may affect test result . Topical antiinflammation treatment aim application area past 2 month . 8 . Participant history acute chronic disease might interfere increase risk study participation . ( e.g. , atopic dermatitis/eczema , systemic lupus erythematosus , rheumatoid arthritis , autoimmune disease , asthma chronic respiratory disease ) . 10 . Participant damage skin close proximity test site ( e.g. , sunburn , uneven skin pigmentation , tattoo , scar , birthmark disfiguration ) . And suffer active skin disorder , condition , visible skin disease might confuse skin reaction test material . 11 . Participant require use emollient upper back throughout study use emollient skin care product upper back past 3 day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>